Pricing Log in Create free account

Mesoblast Limited (MESO) vs Mineralys Therapeutics, Inc. (MLYS)

Mesoblast Limited and Mineralys Therapeutics, Inc. are both Biotechnology companies. Mesoblast Limited and Mineralys Therapeutics, Inc. are of similar size ($1.9B and $1.8B). Mineralys Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Mesoblast Limited leads on 6 and Mineralys Therapeutics, Inc. on 5.

Valuation

Metric MESO MLYS Biotechnology median
P/E n/m n/m 8.50
P/S 137.69 n/m 9.71
P/B 1.80 3.12 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 137.28 n/m 9.21
Earnings yield (8.43%) (20.89%) (33.15%)
Free cash flow yield (8.17%) (8.07%) (25.50%)

Profitability

Metric MESO MLYS Biotechnology median
Gross margin (269.72%) — 65.16%
Operating margin (826.28%) 0.00% 0.00%
Net margin (1,091.71%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (80.88%) (56.36%)
Return on assets 0.00% (69.67%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MESO MLYS Biotechnology median
Revenue growth (TTM) (26.54%) — 6.02%
EPS growth (last fiscal year) 48.24% 37.43% 30.26%
Revenue growth, 5-year CAGR 74.39% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO MLYS Biotechnology median
Debt to equity 0.22 0.18 0.00
Current ratio 1.58 34.46 4.72
Net debt to EBITDA (0.67) 3.85 0.96

Dividend

Metric MESO MLYS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MESO MLYS Biotechnology median
Market cap 1.81b 1.91b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack